In one specific case, a patient with stage IV (cT4N3M1) hormone receptor (HR)-positive and HER2-positive invasive ductal carcinoma, who presented with systemic metastases including the brain, underwent 26 cycles of initial anti-HER2 targeted therapy along with chemotherapy. The gene discussed is ERBB2; the disease is invasive ductal breast carcinoma.